T
Timothy L. Foley
Researcher at Pfizer
Publications - 31
Citations - 960
Timothy L. Foley is an academic researcher from Pfizer. The author has contributed to research in topics: Nonribosomal peptide & In vivo. The author has an hindex of 16, co-authored 30 publications receiving 826 citations. Previous affiliations of Timothy L. Foley include National Institutes of Health & Salk Institute for Biological Studies.
Papers
More filters
Journal ArticleDOI
Manipulation of carrier proteins in antibiotic biosynthesis.
TL;DR: A method to covalently label carrier proteins from PK and NRP synthases using the enzymatic transfer of a modified coenzyme A analog by a 4'-phosphopantetheinyltransferase is described.
Journal ArticleDOI
Site-specific protein modification: advances and applications.
TL;DR: Post-translational modification with functionalized substrate analogues opens up several unique avenues to induce selective reactivity into proteins in a sequence-specific manner, and can be applied to protein identification and manipulation in both in vitro and in vivo contexts.
Journal ArticleDOI
Targeting iron assimilation to develop new antibacterials
Timothy L. Foley,Anton Simeonov +1 more
TL;DR: This review describes recent efforts to develop drugs that interrupt the assimilation of iron by bacteria: a process that is vital to cellular homeostasis and is not currently targeted by antibiotics used in the clinic.
Journal ArticleDOI
An orthogonal active site identification system (OASIS) for proteomic profiling of natural product biosynthesis.
Jordan L. Meier,Sherry Niessen,Heather Hoover,Timothy L. Foley,Benjamin F. Cravatt,Michael D. Burkart +5 more
TL;DR: An orthogonal active site identification system (OASIS) for the proteomic identification and analysis of PKS/NRPS biosynthetic enzymes and offers a valuable tool for strain comparison, culture condition optimization, and enzyme discovery.
Journal ArticleDOI
Azetidine and Piperidine Carbamates as Efficient, Covalent Inhibitors of Monoacylglycerol Lipase
Christopher Ryan Butler,Elizabeth Mary Beck,Anthony R. Harris,Zhen Huang,Laura A. McAllister,Christopher W. am Ende,Kimberly F. Fennell,Timothy L. Foley,Kari R. Fonseca,Steven J. Hawrylik,Douglas S. Johnson,John D. Knafels,Scot Richard Mente,Stephen Noell,Jayvardhan Pandit,Tracy Brown Phillips,Justin R. Piro,Bruce N. Rogers,Tarek A. Samad,Jane Wang,Shuangyi Wan,Michael Aaron Brodney +21 more
TL;DR: Compound 6, a highly efficient and selective MAGL inhibitor against recombinant enzyme and in a cellular context, was tested in vivo and shown to elevate central 2-AG levels at a 10 mg/kg dose.